

110
**Beth Israel Deaconess
Medical Center**

*Director, Biotherapeutics Development Lab
Division of Hematology-Oncology*




0300
Harvard Medical School
CC

Richard P. Junghans, PhD, MD

Beth Israel Deaconess Medical Center
Harvard Institutes of Medicine
4 Blackfan Circle, #403 • Boston, MA 02215 USA
617 432-7004 • FAX 617 432-7007
email: junghans@hms.harvard.edu

*Assistant Professor of Medicine
Member, Harvard Institute of Human Genetics*



October 22, 2003

Director of The United States Patent and Trademark Office
United States Patent and Trademark Office
Washington, D.C. 20231

RE: "Antibodies as Chimeric Effector Cell Receptors against Tumor Antigens" #10/006,773.

To Whom It May Concern:

As requested, attached is a substitute computer readable form (CRF) copy of the "Sequence Listing". An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification with a copy of the 7/24/2003 "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acids Sequence Disclosures" for application No. 10/006,773. The data contained in the CRF are identical to the written sequence and contains no new matter. The late fee of \$210.00 may be charged to my Visa Card Account shown on the attached USPTO Credit Card Payment Form.

Please call my administrative assistant, Cassandra Carter, with any questions.

Thank you.

Sincerely,

Richard P. Junghans, Ph.D., M.D.

Encl.

RPJ/cc